furan/neoplasms

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a composition for the prevention and treatment of cell proliferative disease including cancer which comprises ethyl(2-methyl-3{(E)-[(naphtho[2,1-b]furan-2-ylcarbonyl)hydrazono]methyl}- -1H-indole-1-yl)acetate, the

FIELD OF THE INVENTION The present invention is directed to compounds, methods, and compositions for the treatment of cancer, neurological disorders, and fibrotic disorders. BACKGROUND Every year, cancer claims the lives of more than half a million Americans. Cancer is the second leading cause of

FIELD OF THE INVENTION The present invention is directed to compounds, methods, and compositions for the treatment of cancer, neurological disorders, and fibrotic disorders. BACKGROUND Every year, cancer claims the lives of more than half a million Americans. Cancer is the second leading cause of

FIELD OF THE INVENTION The present invention is directed to compounds, methods, and compositions for the treatment of cancer, neurological disorders, and fibrotic disorders. BACKGROUND Every year, cancer claims the lives of more than half a million Americans. Cancer is the second leading cause of

FIELD OF THE INVENTION The present invention is directed to compounds, methods, and compositions for the treatment of cancer, neurological disorders, and fibrotic disorders. BACKGROUND Every year, cancer claims the lives of more than half a million Americans. Cancer is the second leading cause of

FIELD OF THE INVENTION The present invention relates to compounds that inhibit certain integrins, particularly to compounds that inhibit .alpha..sub.v integrins. BACKGROUND OF THE INVENTION Integrins are a major family of adhesion receptors. They are produced by most cell types and are a means by

FIELD OF THE INVENTION The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in

TECHNICAL FIELD The present invention relates to novel water-soluble prodrugs of 2-acetylnaphtho[2,3-b]furan-4,9-dione, pharmaceutically acceptable salts thereof, or hydrates or solvates thereof useful as a medicament. The invention also relates to pharmaceutical compositions comprising a novel

CROSS-REFERENCE TO RELATED APPLICATION This application is the U.S. national phase applications filed under 35 U.S.C..sctn.371 claims benefit to International Patent Application No. PCT/KR2012/008989, filed on Oct. 30, 2012, which is entitled to priority under 35 U.S.C .sctn.119(a)-(d) to Korea

This application is a .sctn.371 national stage filing of PCT/EP02/09944 filed 5 Sep. 2002. This invention relates to novel compounds and their use as pharmaceuticals, particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine

BACKGROUND Disclosed herein are methods comprising administering to a subject a combination comprising a therapeutically effective amount of at least one compound chosen of formula (I) in combination with a therapeutically effective amount of at least one paclitaxel compound chosen from paclitaxel,

BACKGROUND OF THE INVENTION The present invention relates to a series of novel phosphate ester derivatives containing a cyclic ether system and provides processes for producing these compounds and compositions containing them for use as anti-cancer agents. Many compounds have been shown to have

BACKGROUND OF THE INVENTION 1. The Field of the Invention The present invention relates to human telomerase, a ribonucleoprotein enzyme involved in human telomere DNA synthesis, and to compounds that inhibit telomerase activity. The invention provides methods, compounds and compositions relating to

This application is the U.S. National Phase of International Application PCT/NZ03/00094, filed 19 May 2003, which designated the U.S. PCT/NZ03/00094 claims priority to New Zealand Application No. 519031 filed 17 May 2002. The entire content of these applications are incorporated herein by

FIELD OF THE INVENTION This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a [(1-piperazinyl)-4-pyridinylmethyl]-Naphtho[1,2-b]furan structure which function as inhibitors of Mcl-1 protein, and their use as therapeutics